ICP-B208 for Advanced Solid Tumors
Part of Cancer clinical trials.
This early-stage trial tests a new cancer drug called ICP-B208 in people with advanced solid tumors (like stomach, colon, or other cancers) that have spread or cannot be removed surgically and have not responded to previous treatments. The study aims to find the right dose and see how well the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Advanced cancer that has spread or cannot be surgically removed, confirmed by biopsy
- Previous cancer treatments have not worked
- Good overall health (able to care for yourself with minimal assistance)
- At least one tumor that can be measured on imaging
- Normal organ function (blood counts, liver, kidney, heart)
- Willing to use effective birth control for 6 months after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests CBP-1008, a new experimental treatment, in people with advanced solid cancers that either worsened after standard treatment or for which no standard option exists. It may help doctors learn the safest dose and whether it shows signs of benefit in specific tumor types.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests a new drug, BG-C0902, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it is safe and effective.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.